Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...

Santa Monica, California Monday, February 9, 2026, 12:00 Hrs [IST] ...

The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta (axicabtagene ...

ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in patients with aggressive B Cell No ...

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.

Cognision today unveiled Cognision360tm, a groundbreaking web-based platform that consolidates multiple neurobiomarker data streams into a single, standardized system?addressing one of the ...

Public health recommendations suggest individuals can resume normal activities 5 days after symptom cessation. However, our study finds that full recovery can take longer, indicating that delayed ...

Following an intensive period of consultation, Relmada has received formal regulatory guidance from the FDA for NDV-01 in non-muscle invasive bladder cancer (NMIBC). The agency has agreed to support ...

Investigators evaluated dual immune checkpoint inhibitors for safety and efficacy in patients with brain metastases from rare cancers.

Thousands of Australian parents are struggling with children who cannot go to school. A new podcast and e-book have been released to help support them.

Guillain-Barré Syndrome Presenting as Pseudo-Cerebellar Syndrome: A Case Report from a Resource-Limited Setting in Sub-Saharan Africa Guillain-Barré Syndrome (GBS) is the most frequent cause of acute ...